immunosuppressants [autosaved]
TRANSCRIPT
PRESENTED BY
B.DEVADATHA
M.SCII BMB
DEPT .OF BMB
IMMUNOSUPPRESSANTS
B. Devadatha(123680029)
M. Sc. IInd Year BMB
INTRODUCTION Immunosuppression involves an act that reduces the activation or
efficacy of the immune system
Immunosuppressants are used to control severe manifestations of allergic, autoimmune and transplant-related diseases
Now over 80 autoimmune diseases and several common allergic conditions in which immunosuppressant's are used
Prevent the rejection of transplanted organs and tissues
Treatment of autoimmune diseases or diseases that are most likely of autoimmune origin
Treatment of some other non-autoimmune inflammatory diseases
CLASSIFICATION OF IMMUNOSUPPRESSANTS
1.PHYSICAL IMMUNOSUPRESSANTS
Includes Total Lymphoid Irradiation, Plasmapheresis, thoracic duct drainage
Inhibits Cell division ,cell activation, Antibody production
2.CHEMICAL IMMUNOSUPPRESSANTS:
I. Corticosteroids
II. Cytostatics
III. Antibodies
IV. Drugs acting on Immunophilins
3.BIOLOGICAL IMMUNOSUPPRESSANTS:
interferon's, interleukins, colony-stimulating factors, monoclonal antibodies
PHYSICAL IMMUNOSUPPRESSANTS Total Lymphoid Irradiation (TLI ):
Fractionated irradiation focused on Lymphoid tissues, with shielding of Bone marrow, Lungs ,Non lymphoid tissues
Induces formation of large granular Lymphocytes lacking T,B & Macrophage markers which non specifically suppresses Ag –specific cytolytic arm of Allogenic immune reactions
TLI can induce true Transplantation tolerance to Renal allografts in humans
UV-B light is absorbed by skin Urocanic acid & undergoes isomerization to Cis form which induces suppression through effect on Dendritic APC
Adverse Effects: Myelosuppression
Skin changes
Nausea and vomiting
PHYSICAL IMMUNOSUPPRESSANTS Plasmapheresis:
removing plasma hemocomponent that is circulating with pathogens and replacing it with a suitable solution
Useful adjunct to chemotherapy for removing circulating immunoglobulins or immunoglobulin components in multiple myeloma and other dysproteinemias
Rapidly removes pathogenic antibody Must be combined with B lymphotoxic drug to prevent
rebound (e.g. cyclophosphamide, steroids) Combination with IVIg very powerful Risks include cardiovascular instability
PHYSICAL IMMUNOSUPPRESSANTS
Thoracic duct drainage: Woodruff demonstrated that synergism of
thoracic-duct drainage with lymphoid-depleting modality, antilymphocyte serum
effective and safe in decreasing the immunologic response of the recipient of renal transplants from genetically related donors
Lymphocytapheresis using TDD is very selective for removing lymphocytes (especially helper T-cells)
CHEMICAL IMMUNOSUPRESSANTS
• Corticosteroids: Prednisone , Prednisolone
Dexamethasone,Methylpredinsolone They have both anti-inflammatory action and
immunosuppressant effects
Mechanism of action: bind to glucocorticoid receptors and the complex interacts with
DNA to inhibit gene transcription of inflammatory genes
stimulates migration of T cells from intravascular tissue to lymph nodes
Inhibit mitosis of lymphocytes
Reduce size and lymphoid content of the lymph node and spleen
Inhibit the production of inflammatory mediators, including PAF, leukotrienes, prostaglandins, histamine and bradykinin
Decrease production of cytokines IL-1, IL-2, interferon, TNF
Corticosteroids
Dosage: Maintenance up to 20 mg/day; treatment of rejection 200 mg/day for 3 dats or 3 days
Adverse Effects: Sodium and fluid retention, Muscle weakness, Steroid myopathy, Loss of muscle mass and osteoporosis, Peptic ulcer with possible perforation and
hemorrhage; Pancreatitis, impaired wound healing, thin fragile skin Increased tendency to diabetes mellitus Hypertension
Cytostatics Cytostatics inhibit cell division
In immunotherapy, they are used in smaller doses than in the treatment of malignant diseases.
They affect the proliferation of both T cells and B cells.
Due to their highest effectiveness, purine analogs are most frequently administered.
It includes the following: Alkylating agents; Antimetabolites
ALKYLATING AGENTS:
The alkylating agents used in immunotherapy are nitrogen mustards (cyclophosphamide), nitrosoureas, platinum compounds, and others
In small doses, it is very efficient in the therapy of systemic lupus erythematosus, autoimmune hemolytic anemias,Wegener's granulomatosis and other immune diseases
Cyclophosphamide
Cyclophosphamide is an alkylating agent. It is a widely used as a cytotoxic agent.
It is given orally as well as intravenously with efficacy
Mechanism of action: suppress bone marrow function
It is inactive in parent form, and must be activated to cytotoxic form by liver CYT450 liver microsomal system to 4‐Hydroxycyclophamide and Aldophosphamide. 4‐Hydroxycyclophamide and Aldophosphamide are delivered to the dividing normal and tumor cells.
Aldophosphamide is converted into acrolein and phosphoramide mustard.They crosslink DNAs resulting in inhibition of DNA synthesis
Side effects: Usually large Doses of cyclophosphamide is associated with ‐
a. Pancytopenia
b. Hemorrhagic cystitis
c. Nausea and vomiting
d. Cardiac toxicity
e. Electrolyte imbalances
ANTIMETABOLITES
Includes folic acid analogues, such as methotrexate; purine analogues such as azathioprine and mercaptopurine pyrimidine analogues; protein synthesis inhibitors
Azathioprine : Prodrug that releases 6-mercaptopurine Mechanism of Action: Converts 6-mercaptopurine to tissue inhibitor of metalloproteinase, which
is converted to thioguanine nucleotides that interfere with DNA synthesis; thioguanine derivatives may inhibit purine synthesis
Uses: a. Used for graft rejectionMycophenolate mofetil
b. Normally used in combination with corticosteroids. Side effects: Bone marrow suppression (leukopenia, anemia), Skin rashes,nausea Liver toxicity ,macrocytosis
Azathioprine
Mycophenolate mofetil Mycophenolic acid from penicillium molds
Mechanism of Action:
Prevents T- and B-cell proliferation by inhibition of de novo purine synthesis by inhibition of inosine monophosphate dehydrogenase
Dosage 1 to 2 g/day in divided doses
CLINICAL USE:
Solid organ transplants for refractory rejection.
Steroid-refractory hematopoietic stem cell transplant patients.
Combined with prednisone as alternative to CSA or tacrolimus.
Rheumatoid arthritis, & dermatologic disorders.
Adverse Effects:
Leukopenia, neutropenia.
Lymphoma
GIT toxicity
Leflunomide Pyrimidine synthesis inhibitor
Active metabolite undergoes enterohepatic circulation
Arava oral administration as tablets containing 10, 20, or 100 mg
Mechanism of Action:
Dihydroorotate dehydrogenase inhibitor
antiproliferative activity
CLINICAL USE:
rheumatoid arthritis
Organ transplant
Adverse Effects:Elevation of liver enzymesRenal impairmentTeratogenicityCardiovascular effects
Methotrexate
a folic acid antagonist
Mechanism of Action:
Inhibits dihydrofolate reductase required for folic acid activation (tetrahydrofolic)
Inhibition of DNA, RNA &protein synthesis
Interferes with T cell replication.
Rheumatoid arthritis & psoriasis and Crohn disease
Adverse effects
Nausea-vomiting-diarrhea
Alopecia
Bone marrow depression
Pulmonary fibrosis
Renal & hepatic disorders
Antibodies
block T cell surface molecules involved in signaling immunoglobulins
They are of two types:
Polyclonal antibodies & Monoclonal antibodies
Polyclonal antibodies:
obtained from plasma or serum of horses hyper-immunized with human lymphocytes.
Inhibit T lymphocytes and cause their lysis, which is both complement mediated cytolysis and cell-mediated opsonization followed by removal of reticuloendothelial cells from the circulation in the spleen and liver.
• Antithymocyte globulin (ATG)• Antilymphocyte globulin (ATGAM)
Polyclonal antibodies
Mechanism of Action:
agents contain antibodies specific for many common T cell antigens including CD2, CD3, CD4, CD8, CD11a, CD18
Blocks T-cell membrane proteins (CD2,CD3, CD45, and so forth), causing altered function, lysis, and prolonged T-cell depletion
CLINICAL USE: Combined with cyclosporine for bone marrow
transplantation. To treat acute allograft rejection. Steroid-resistant rejection. Adverse Effects:
Leukopenia ,Thrombocytopenia
serum sickness
muscle pain
lymphopenia
Monoclonal antibodies Monoclonal antibodies are antigen-specific immunosuppressants that will
reduce immune response to alloantigens of the graft while preserving the response to alloantigens to unrelated antigens
Early rejection prophylaxis and treatment of rejection.
Muromonab-CD3 (OKT3):
Directed against CD3 component of T-cell–receptor
signal-transduction complex
Mechanism of Action:
Binds to CD3 associated with T-cell receptor,leading to initial activation and cytokine release, followed by blockade of function, lysis, and T-cell depletion
Adverse Effects: Severe cytokine-release syndrome, pulmonary edema, acute renal
failure, gastrointestinal disturbances, changes in central nervous system
Alemtuzumab Humanized monoclonal antibody against CD52
Approved for use in B-cell chronic lymphocytic leukemia
Mechanism of Action:
Binds to CD52 on all B and T cells, most monocytes, macrophages, and natural killer cells, causing cell lysis and prolonged depletion
Efficacy: effective as induction therapy for the prevention of acute rejection in
kidney, liver, pancreas, intestinal, and lung transplants
Adverse Effects:
pancytopenia, neutropenia, thrombocytopenia, and lymphopenia
hypotension, fever, shortness of breath
Basiliximab and Daclizumab
Basiliximab is a chimeric human-mouse IgG
(25% murine, 75% human protein). Daclizumab is a humanized IgG (90% human protein). Mechanism of Action:
Binds to and blocks the interleukin-2–Receptor a chain (CD25 antigen) on activated T cells, depleting them and inhibiting interleukin-2–induced T-cell activation
Efficacy:
Both basiliximab and daclizumab are approved for use in kidney transplantation in combination with cyclosporine and corticosteroids
Adverse Effects:
Hypersensitivity reactions (uncommon)
gastrointestinal disorders
Drugs acting on Immunophilins
Cyclosporine: 11-amino-acid cyclic peptide from Tolypocladium inflatum
Mechanism of Action:
Binds to cyclophilin intracellular protein receptors
complex inhibits calcineurin phosphatase and T-cell activation
CLINICAL USE:
Kidney, liver, heart organ transplantation used in combination with azathioprine and corticosteroids
Adverse Effects: Nephrotoxicity, hemolytic–uremic syndrome, hypertension
neurotoxicity, gum hyperplasia
skin changes ,hirsutism,
post-transplantation diabetes mellitus
hyperlipidemia
Tacrolimus (FK506) Macrolide antibiotic From Streptomyces tsukubaensis
Mechanism of Action:
Binds to FK-binding protein 12; inhibits synthesis and release of IL-2
CLINICAL USE: Organ and stem cell transplantation Prevention of rejection of liver and kidney transplants (with
glucocorticoids). TAC is 10 – 100 times more potent than CsA in inhibiting
immune responses
Toxic effects :
lower incidence of hypertension, hyperlipidemia, skin changes, hirsutism, and gum hyperplasia
higher incidence of post-transplantation diabetes mellitus and neurotoxicity
Sirolimus (Rapamycin)
Triene macrolide antibiotic from Streptomyces hygroscopicus from
Easter Island
Mechanism of Action:
Binds to FKBP12; complex inhibits target of rapamycin and interleukin-2–driven T-cell proliferation
Blocks the progression of activated T cells from G1 to S phase of cell cycle
Efficacy:
approved for the prophylaxis of rejection in kidney transplant patients
treatment of variety of tumors including small cell lung cancer, pancreatic cancer, leukemia ,lymphoma, rhabdomyosarcoma, neuroblastoma
Adverse Effects:
Hyperlipidemia, increased toxicity of calcineurin inhibitors,
thrombocytopenia, delayed wound healing,
delayed graft function
New Immunosuppressive Drugs
derived from myriocin, a fungus-derived sphingosine analogue
Mechanism of Action:
Works as an antagonist for sphingosine-1-phosphate receptors on lymphocytes, enhancing homing to lymphoid tissues and preventing egress, causing lymphopenia
• Prescribed for– Renal transplant– Multiple sclerosis
• Side effect– Reversible first-dose bradycardia, potentiated by general
anesthetics and beta-blockers– nausea, vomiting, diarrhea, increased liver-enzyme
New Immunosuppressive Drugs Etanercept (Enbrel)
Recombinant DNA drug binds TNF (tumor necrosis factor) in the circulation and
in the joint, preventing interaction with cell surface TNF receptors thereby reducing TNF activity
Subcutaneous injection Side effects Susceptibility to opportunistic infection
ISA 247 novel isomeric cyclosporine A analog mixture a
calcineurin inhibitor. treatment of psoriasis and prevention of organ rejection
after transplantation
REFERENCE TEXT BOOKS:
JANEWAY’S Immunobiology 7th ed
Kuby Immunology.6th ed
Ivan Roitt Essential Immunology 11th ed
WEBSITES & JOURNALS
Immunosuppression after Liver Transplantation http://gft.sagepub.com
www.accesspharmacy.com.proxy.lib.umich.edu/popup.aspx?aID=7996230&print=yes 1/
The new england journal Of medicine www.nejm.org
Erasmus Journal of Medicine • vol 1 - nr 2 - January 2011
Ultraviolet A Radiation: Its Role in Immunosuppression and Carcinogenesis
Current Concepts of Immunosuppression and Side Effects Anand Khurana and Daniel C. Brennan
Pancreas-Kidney Transplantation: Drugs (http:/ / www. pancreas-kidney. com/ drugs. html), a brief history of immunosuppressive drugs. Accessed on 21 August 2005
Immunosuppressants, Pharmacologic profile (http:/ / www. drugguide. com/ classification_articles/ immunosuppressants. htm). Drugguide.com. Accessed on 21 August 2005